Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody ...

Explore the role of patient-derived biology in enhancing antibody-drug conjugates for more effective cancer treatment.

Explore how the future of obesity drugs starts in preclinical discovery, addressing global challenges and advancing treatment ...

Developed at Sanford Burnham Prebys and published in npj Precision Oncology , DeepTarget challenges a long-standing ...

This article is based on a poster originally authored by Peter Hsueh, Lili Qin, Jane Liu and Wenlin Ren. Target proteins are central to the antibody discovery process. These reagents play a critical ...

The FDA’s emerging framework represents more than a regulatory update; it is a paradigm shift toward human-relevant, ...

GUEST COMMENTARY—For millions of patients, the slow pace of drug discovery means years – sometimes decades – without effective treatments. Many diseases remain untreatable, not because they are rare ...

Nona Biosciences is a global biotechnology company committed to cutting-edge technology innovations and providing integrated solutions from I to I (R) (Idea to IND), ranging from target validation and ...

Smart multi-target drugs are reshaping modern therapeutics by addressing the complex, interconnected pathways that drive diseases like Alzheimer’s, cancer, and major depressive disorder. Advances in ...

Zoliflodacin, which will be marketed under the name Nuzolvence, is the first new drug to uniquely target gonorrhea infections in decades, and the first developed as part of a public-private ...